Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519854 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL937458 | 0.94 | CXCR4 (0.35) | CXCR4SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3662239 | 0.92 | CXCR4 (0.33) | CXCR4SMN1; SMN2ALDH1A1 | |
| SCHEMBL22183528 | 0.91 | CXCR4 (0.41) | CXCR4SMN1; SMN2ALDH1A1HIF1AMAPT | |
| 4,4-Difluoro-Piperidinium SCHEMBL13457 | 0.85 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL19410291 | 0.82 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL16582 | 0.82 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL29154751 | 0.82 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL1000443 | 0.82 | — | — | |
| 4,4-Difluoro-Piperidinium SCHEMBL27142480 | 0.82 | HIF1A (0.33) | HIF1AMAPTPDE4AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CXCR4 2449/4885SMN1; SMN2 1842/4885ALDH1A1 1575/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CXCR4 2449/4885SMN1; SMN2 1842/4885ALDH1A1 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.